Sales of the blood-clotting drug Kogenate
were level year on year as expected, while business with the multiple sclerosis drug Betaferon /Betaseron declined by 16.
Hypersensitivity reactions, including anaphylaxis have been reported with Kogenate
Sur le plan medical, le Kogenate
qui a, depuis son introduction en Algerie, a ameliore, significativement, le traitement des hemophiles, fetera ses 25 annees d'existence cette annee.
The company has a strong development program dedicated to hemophilia including ongoing clinical investigations into long-acting forms of Kogenate
Sales of the Kogenate
bleeding treatment rose 16% to 205 million euros, while sales of Betaseron for multiple sclerosis increased 10% to 264 million euros.
The drug Kogenate
FS is the next generation blood-clotting factor that helps hemophiliacs survive.
Current growth drivers include: Avalox/Avelox (moxifloxacin), Betaferon/Betaseron (interferon beta-1b), Kogenate
(Factor VIII), Levitra (vardenafil), Mirena (levonorgestrel), Yasmin (ethinyloestradiol+drospirenone) and Aspirin Cardio.
Our study shows you individual revenue forecasts to 2024 for 10 marketed products, including these: -- Advate -- NovoSeven -- Kogenate
-- BeneFIX -- FEIBA.
In addition to housing the state-of-the-art Kogenate
biological manufacturing facility, Berkeley will remain an important global R&D center for protein-based biologics drug discovery and development and will continue to be home to the company's Global Hematology/Cardiology business unit.
4 million over the first half 2009 of Kogenate
royalties in connection with the favourable settlement of the litigation between the Group and Bayer, (ii) the purchase price accounting impact related to the Group's transaction in North America over the two periods as well as (iii) non-recurring costs incurred in 2010.
As part of our longstanding commitment to the hemophilia community, we are eager to share clinical data from our LEOPOLD trials on the investigational product BAY 81-8973 and from the SPINART trials on Kogenate
FS antihemophilic factor (recombinant)," said Dario Mirski, M.
The presentations will describe the results from a Phase III study with octocog alfa (approved for hemophilia A under the trade name of Kogenate
Bayer in the EU)) as well as clinical and non-clinical results on damoctocog alfa pegol (BAY 94-9027) for hemophilia A therapy.